Single-Gene Immune Defects Reveal Molecular Drivers Underlying Severe Allergic Disorders

In a scientific review published in Frontiers in Allergy, researchers Margherita Perlato, Edoardo Cataudella, Cristina Scaletti, and Lorenzo Cosmi examine how rare inborn errors of immunity illuminate the precise molecular mechanisms that drive type 2 inflammation. While allergic conditions have traditionally been evaluated as complex multifactorial disorders arising from interactions between environmental exposures and polygenic susceptibility, the identification of primary atopic disorders demonstrates that single-gene alterations are capable of producing profound allergic phenotypes. By evaluating paradigmatic monogenic conditions, the authors outline how disparate molecular pathways converge on shared allergic disease features, establishing a biological framework for understanding type 2 immune dysregulation across rare and common clinical settings.

Type 2 inflammation functions physiologically as a coordinated defense mechanism against helminthic infections and contributes to tissue repair, yet its dysregulation underlies the pathology of widespread allergic diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy, and eosinophilic esophagitis. This immune program recruits both innate and adaptive components, centrally driven by type 2 T helper lymphocytes and type 2 innate lymphoid cells that release interleukin-4, interleukin-5, and interleukin-13. These cytokines stimulate immunoglobulin E synthesis and drive the recruitment and activation of basophils, eosinophils, and mast cells through molecular networks integrating cytokine-receptor modules such as JAK1-STAT6, multi-protein signalosomes like CARD11-BCL10-MALT1, and lineage-defining transcription factors including GATA3.

The epidemiological scope of allergic pathology is vast, affecting approximately 20 percent of the global population, with atopic dermatitis alone impacting an estimated 11 percent of children and adolescents alongside 6 percent of adults across varied geographical regions. Within the clinical spectrum of inborn errors of immunity, allergic manifestations are increasingly recognized; in the updated International Union of Immunological Societies classification comprising 508 genes across 559 conditions, more than 50 monogenic disorders are associated with primary atopic disorders. A multinational survey of 8,450 patients with inborn errors of immunity across 23 countries documented allergic diseases in a median of 16.3 percent of cases, serving as the initial clinical presentation in 8 percent, while genomic sequencing across 998 individuals with atopic dermatitis identified monogenic contributing variants in 25 patients.

Among the primary molecular mechanisms reviewed, impaired T-cell receptor signaling provides insight into paradoxical allergic skewing, as illustrated by dominant-interfering heterozygous mutations in CARD11. Because weak antigen-receptor stimulation favors type 2 helper T-cell polarization over type 1 differentiation, disruption of the lymphocyte scaffold protein CARD11 directly alters downstream signaling pathways. In CARD11-associated atopy with dominant interference of NF-kappa-B signaling, compromised assembly of the CARD11-BCL10-MALT1 signalosome reduces JNK activation, which consequently upregulates the expression of key type 2 transcription factors GATA3 and NFATC1. Through this mechanism, diminished TCR activation bypasses protective counter-regulation to actively foster type 2 immune differentiation.

Dysregulated cytokine signaling represents a second paradigmatic route, as observed in patients harboring germline heterozygous gain-of-function variants in STAT6. Under physiological conditions, interleukin-4 and interleukin-13 binding triggers Janus kinases to phosphorylate STAT6, driving dimerization, nuclear translocation, and transcription of genes essential for type 2 differentiation and immunoglobulin E class switching. STAT6 gain-of-function variants amplify this signaling cascade, producing marked type 2 skewing among circulating CD4-positive T cells with elevated GATA3, CRTH2, and CCR4 expression alongside reductions in Th1 and Th17 subsets. Furthermore, patient analyses revealed increased circulating CD19-positive CD27-positive IgE-positive B cells and heightened IgE class switching upon in vitro stimulation with interleukin-4 and CD40.

Loss of immune tolerance provides a third pathway driving allergic pathology, exemplified by immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome caused by loss-of-function variants in FOXP3. As the essential transcriptional regulator of regulatory T cell identity and suppressive function, functional defects in FOXP3 disrupt immunological tolerance and allow autoreactive and allergic immune responses to emerge concurrently. Specific FOXP3 mutations skew dysfunctional regulatory T cells toward a type 2 phenotype characterized by aberrant GATA3 expression, interleukin-4 and interleukin-13 production, and defective suppression of effector cells. Single-cell analyses confirmed that unstable regulatory T cells in affected patients acquire type 2 effector-like functions alongside expanding autoreactive T cell clones.

Cytoskeletal and immunological synapse abnormalities also link monogenic immunodeficiencies directly to severe atopic disease, as documented in DOCK8 deficiency. DOCK8 acts as a guanine nucleotide exchange factor activating CDC42 to regulate actin cytoskeleton organization, cellular migration, and immunological synapse formation, with patient-derived CD4-positive T cells displaying pronounced type 2 skewing and elevated interleukin-4, interleukin-5, and interleukin-13 production alongside decreased Th1 and Th17 responses. Investigations in DOCK8-deficient murine models revealed that migrating mononuclear phagocytes undergo structural shattering termed cytothripsis. This cellular disintegration releases interleukin-1-beta, triggering GM-CSF production by CD4-positive T cells and ultimately driving the excessive production of type 2 inflammatory cytokines.

Epithelial barrier and signaling defects demonstrate how non-hematopoietic structural tissues actively initiate type 2 inflammation, a concept exemplified by Netherton syndrome resulting from biallelic loss-of-function variants in SPINK5. The SPINK5 gene encodes the serine protease inhibitor LEKTI, whose absence permits unchecked epidermal protease activity, predominantly mediated by kallikrein 5. This enzymatic hyperactivity degrades corneodesmosomal structural proteins to compromise physical skin integrity while simultaneously cleaving protease-activated receptor 2 on keratinocytes. Activation of this receptor directly induces production of thymic stromal lymphopoietin and inflammatory mediators independently of environmental exposure or adaptive immunity, a mechanism validated in mouse models where genetic ablation of kallikrein 5 normalized epidermal architecture and thymic stromal lymphopoietin levels.

Clinically, primary atopic disorders exhibit manifestations that largely overlap with conventional allergic diseases, including eczema, asthma, food allergies, and allergic rhinitis, complicating direct recognition. Key diagnostic indicators that distinguish monogenic defects include unusually early onset, severe disease intensity, poor responsiveness to conventional therapies, extreme hyper-IgE, and pronounced eosinophilia. Patients may also present with broader syndromic clues, such as severe viral skin infections from herpes simplex virus, human papillomavirus, or molluscum contagiosum seen in DOCK8 deficiency; short stature linked to dual immune and growth-hormone signaling impairment in STAT5B deficiency; and connective tissue abnormalities or retained primary dentition characteristic of STAT3-Hyper-IgE syndrome.

The review underscores that elucidating the precise molecular drivers in primary atopic disorders directly guides targeted therapeutic interventions. Monoclonal blockade of interleukin-4 and interleukin-13 signaling via dupilumab has demonstrated clinical efficacy in patients with STAT6 gain-of-function disease by neutralizing upstream cytokines, as well as in patients with CARD11-associated atopy whose primary lesion resides in antigen-receptor signaling. Furthermore, small-molecule kinase inhibitors such as ruxolitinib have successfully targeted upstream Janus kinases in STAT6 gain-of-function cases, restoring Th1 and Th17 populations, lowering eosinophil counts, and improving severe dermatitis, with related efficacy documented using ruxolitinib, baricitinib, and upadacitinib in patients carrying activating JAK1 mutations.

The therapeutic landscape across primary atopic disorders also illustrates that inflammatory pathways extending beyond classical type 2 cascades can shape clinical outcomes, as seen in Netherton syndrome where the interleukin-17 inhibitor secukinumab significantly alleviated cutaneous inflammation, pruritus, and overall disease burden. Despite these promising therapeutic observations, the authors caution that the current clinical evidence for targeted biologics and small molecules in primary atopic disorders remains predominantly derived from single case reports and small cohorts rather than controlled clinical trials. Continued genomic profiling and mechanistic studies in extreme allergic phenotypes promise to expand actionable diagnostic strategies and advance precision therapies for both rare genetic defects and broader atopic populations.

Subject of Research: Molecular mechanisms and targeted therapies in primary atopic disorders driving type 2 inflammation

Article Title: Type 2 inflammation through the lens of inborn errors of immunity

Article References: Perlato, M., Cataudella, E., Scaletti, C., & Cosmi, L. (2026). Type 2 inflammation through the lens of inborn errors of immunity. Frontiers in Allergy, 7, Article 2010211. https://doi.org/10.3389/falgy.2026.2010211

Image Credits: AI Generated

DOI: 10.3389/falgy.2026.2010211

Keywords: primary atopic disorders, type 2 inflammation, inborn errors of immunity, CARD11, STAT6, DOCK8 deficiency, Netherton syndrome, targeted therapies, Type, inflammation, lens, inborn